Akari Therapeutics PLC ADR | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
2.00
8.00
10.10
39.70
42.90
35.80
Gross Income
2.00
8.00
10.10
39.70
42.90
35.80
SG&A Expense
3,593.50
10,127.80
11,269.90
27,592.50
35,417.50
22,617.40
EBIT
3,595.50
10,135.70
11,280.10
27,632.10
35,460.40
22,653.20
Unusual Expense
269.20
546.80
7,860.30
8,673.10
119.80
5,928.90
Non Operating Income/Expense
81.80
19.90
134.60
227.40
375.90
63.50
Interest Expense
201.40
-
25,978.20
-
-
-
Pretax Income
3,609.50
9,608.90
45,232.40
18,589.40
35,778.80
16,438.90
Income Tax
-
-
-
573.70
-
-
Consolidated Net Income
3,609.50
9,608.90
45,232.40
18,015.80
35,778.80
16,438.90
Net Income
3,609.50
9,608.90
45,232.40
18,015.80
35,778.80
16,438.90
Net Income After Extraordinaries
3,609.50
9,608.90
45,232.40
18,015.80
35,778.80
16,438.90
Net Income Available to Common
3,609.50
9,608.90
45,232.40
18,015.80
35,778.80
16,438.90
EPS (Basic)
16.95
17.93
4.99
1.99
3.03
1.07
Basic Shares Outstanding
210.80
541.20
8,520.90
11,776.90
12,472.90
15,403.10
EPS (Diluted)
17.13
17.71
5.31
1.53
2.87
1.07
Diluted Shares Outstanding
210.80
542.70
8,520.90
11,776.90
12,472.90
15,403.10
EBITDA
3,593.60
10,127.80
11,269.90
27,592.50
35,417.50
22,617.40
Non-Operating Interest Income
-
-
20.70
142.20
177.30
221.90
About Akari Therapeutics
View Profile
